

DAFTAR PUSTAKA

- [1] WHO, *Global Tuberculosis Report 2024 (2024th ed)*. 2024.
- [2] Kemenkes RI, "Revisi Strategi Nasional Penanggulangan Tuberkulosis Di Indonesia 2020-2024 dan Rencana Interim 2025-2026," p. 286, 2023.
- [3] S. Shukla, N. Bhardwaj, Singh, and Ashutosh, "Drug resistance in *Mycobacterium tuberculosis*: An evolutionary perspective and its adaptation to the lung microenvironment," Elsevier Ltd, 2024.
- [4] R. Singh, S. P. Dwivedi, U. S. Gaharwar, R. Meena, P. Rajamani, and T. Prasad, "Recent updates on drug resistance in *Mycobacterium tuberculosis*," *J. Appl. Microbiol.*, vol. 128, no. 6, pp. 1–21, 2019.
- [5] K. V. Rudraraju, D. Aggarwal, Z. Zhang, and Yin, "Therapeutic targeting of protein tyrosine phosphatases from *Mycobacterium tuberculosis*," *Microorganisms*, vol. 9, no. 1, pp. 1–13, 2021.
- [6] N. D. Thanh *et al.*, "Synthesis, biological evaluation and molecular docking study of 1,2,3-1H-triazoles having 4H-pyrano[2,3-d]pyrimidine as potential *Mycobacterium tuberculosis* protein tyrosine phosphatase B inhibitors," *Bioorganic Med. Chem. Lett.*, vol. 29, no. 2, pp. 164–171, 2019.
- [7] M. Jain, S. Gollapudi, Khatik, and G. L., "An Insight into MtpB Inhibitors as a Key Strategy to Treat MDR and XDRTuberculosis," *Curr. Pharm. Des.*, vol. 29, no. 8, pp. 562–575, 2023.
- [8] S. Zhang *et al.*, "Triazole derivatives and their anti-tubercular activity," *Eur. J. Med. Chem.*, vol. 138, pp. 501–513, 2017.
- [9] A. A. Ali *et al.*, "Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents," *Bioorganic Med. Chem. Lett.*, vol. 27, no. 16, pp. 3698–3703, 2017.
- [10] K. M. Naidu, S. Srinivasarao, N. Agnieszka, A. K. Ewa, M. M. K. C. Kumar, and K. V. G. Sekhar, "Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various

- ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives,” *Bioorganic Med. Chem. Lett.*, vol. 26, no. 9, pp. 2245–2250, 2016.
- [11] D. Ramesh *et al.*, “Novel pyrimidine – Imines against tuberculosis: Rationale, *in vitro*, *in silico* studies and mechanistic insights,” *J. Mol. Struct.*, vol. 1292, p. 136183, 2023.
- [12] A. M. B. Amorim, L. F. Piochi, A. T. Gaspar, A. J. Preto, N. Rosário-Ferreira, and I. S. Moreira, “Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction,” *Chem. Res. Toxicol.*, vol. 37, no. 6, pp. 827–849, 2024.
- [13] A. L. Nasyanka, D. Ratnasari, J. Na’imah, and D. Kesuma, “Studi *in silico*: Hubungan Kuantitatif Struktur-Aktivitas Antivirus SARS-COV2 Pada Senyawa Turunan N-4-benzoil-N’-(4-fluorofenil) tiourea,” *J. Syifa Sci. Clin. Res.*, vol. 4, no. 1, pp. 509–516, 2022.
- [14] B. Suay-Garcia, J. I. Bueso-Bordils, A. Falcó, M. T. Pérez-Gracia, G. Antón-Fos, and P. Alemán-López, “Quantitative structure–activity relationship methods in the discovery and development of antibacterials,” *Wiley Interdiscip. Rev. Comput. Mol. Sci.*, vol. 10, no. 6, pp. 1–13, 2020.
- [15] E. Yuanita, Sudirman, N. K. T. Dharmayani, M. Ulfa, and J. Syahri, “Quantitative structure–activity relationship (QSAR) and molecular docking of xanthone derivatives as anti-tuberculosis agents,” *J. Clin. Tuberc. Other Mycobact. Dis.*, vol. 21, no. November, p. 100203, 2020.
- [16] K. Mar’iyah and Zulkarnain, “Patofisiologi penyakit infeksi tuberkulosis,” *Pros. Biol. Achiev. Sustain. Dev. Goals with Biodivers. Confronting Clim. Chang.*, vol. 7, no. 1, pp. 88–92, 2021.
- [17] D. P. Maison, “Tuberculosis pathophysiology and anti-VEGF intervention,” *J. Clin. Tuberc. Other Mycobact. Dis.*, vol. 27, no. 1, pp. 100–300, 2022.
- [18] A. A. Agyeman and R. Ofori-Asenso, “Tuberculosis—an overview,” *J. Public Heal. Emerg.*, vol. 1, no. 7, pp. 1–12, 2017.
- [19] P. Chandra, S. J. Grigsby, Philips, and J. A., “Immune evasion and provocation by *Mycobacterium tuberculosis*,” *Nat. Rev. Microbiol.*, vol. 20,

- no. 12, pp. 750–766, Dec. 2022.
- [20] M. Pai *et al.*, “Tuberculosis,” *Nat. Rev. Dis. Prim.*, vol. 2, p. 23, 2016.
- [21] D. M. Lewinsohn *et al.*, “Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children,” *Clin. Infect. Dis.*, vol. 64, no. 2, pp. 1–33, 2016.
- [22] L. Luies and I. du Preez, “The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications,” *Clin. Microbiol. Rev.*, vol. 33, no. 4, Sep. 2020.
- [23] Q. Chai, Y. Zhang, Liu, and C. Hua, “*Mycobacterium tuberculosis*: An Adaptable Pathogen Associated With Multiple Human Diseases,” *Front. Cell. Infect. Microbiol.*, vol. 8, 2018.
- [24] S. S. R. Alsayed and H. Gunosewoyo, “Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets,” *Int. J. Mol. Sci.*, vol. 24, no. 6, p. 5202, Mar. 2023.
- [25] R. Kemenkes, “TATA LAKSANA TUBERKULOSIS,” Fathiyah Isbaniyah.
- [26] T. Irianti and U. G. Mada, *Anti-Tuberculosis*, 2016.
- [27] S. S. Padgilwar *et al.*, “Recent advances in treatment for tuberculosis: A review,” *Int. J. Pharm. Sci. Rev. Res.*, vol. 40, no. 2, pp. 162–172, 2016.
- [28] S. V. Gordon and T. Parish, “Microbe profile: *Mycobacterium tuberculosis*: Humanity’s deadly microbial foe,” *Microbiol. (United Kingdom)*, vol. 164, no. 4, pp. 437–439, 2018.
- [29] A. S. W. Ningsih, A. M. Ramadhan, Rahmawati, and Dewi, “Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia Literature,” 2022.
- [30] J. L. Khawbung, D. Nath, Chakraborty, and Supriyo, “Comparative Immunology , Microbiology and Infectious Diseases Drug resistant Tuberculosis : A review,” *Comp. Immunol. Microbiol. Infect. Dis.*, vol. 74, p. 101574, 2021.

- [31] I. Banjuradja and G. Singh, "Mekanisme hepatotoksisitas dalam tatalaksana tuberkulosis pada gangguan hati," *Indones. J. Chest* |, vol. 7, no. 2, pp. 55–64, 2020.
- [32] S. K. Narang, "Extensively drug resistant tuberculosis (XDR-TB)," *JK Sci.*, vol. 5, no. 2, pp. 102-1026–43, 2019.
- [33] N. Dookie, S. Rambaran, N. Padayatchi, S. Mahomed, and K. Naidoo, "Evolution of drug resistance in *Mycobacterium tuberculosis*: a review on the molecular determinants of resistance and implications for personalized care," *J. Antimicrob. Chemother.*, vol. 73, no. 5, pp. 1138–1151, 2018.
- [34] L. He *et al.*, "ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in *Mycobacterium tuberculosis*," *Tuberculosis*, vol. 95, no. 2, pp. 149–154, 2015.
- [35] J. G. Jang and J. H. Chung, "Diagnosis and treatment of multidrug-resistant tuberculosis," *Yeungnam Univ. J. Med.*, vol. 37, no. 4, pp. 277–285, 2020.
- [36] T. Rinanda, "Kajian Molekuler Mekanisme Resistensi *Mycobacterium tuberculosis*," *J. Kedokt. Syiah Kuala*, vol. 15, no. 3, pp. 162–167, 2015.
- [37] L. Nguyen, "Antibiotic resistance mechanisms in *M. tuberculosis*: an update," *Arch. Toxicol.*, vol. 90, no. 7, pp. 1585–1604, 2016.
- [38] R. Samir *et al.*, "Overcoming *Mycobacterium tuberculosis* Drug Resistance : Novel Medications and Repositioning Strategies," *ACS Omega*, vol. 8, no. 1, p. 13, 2023.
- [39] N. K. Dutta *et al.*, "Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen Noton," *ACS Infect Dis*, vol. 2, no. 3, pp. 231–239, 2016.
- [40] S. Cheng *et al.*, "Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as *Mycobacterium tuberculosis* protein tyrosine phosphatase B inhibitors," *Bioorg. Med. Chem.*, vol. 73, p. 117006, 2022.
- [41] D. Chen, H. Chen, Z. She, and Y. Lu, "Identification of Bostrycin Derivatives as Potential Inhibitors of *Mycobacterium tuberculosis* Protein

- Tyrosine Phosphatase (MptpB),” *Med. Chem. (Los. Angeles)*, vol. 12, no. 3, pp. 296–302, 2016.
- [42] M. H. Shaikh *et al.*, “1,2,3-Triazole derivatives as antitubercular agents: synthesis, biological evaluation and molecular docking study,” *Medchemcomm*, vol. 6, no. 6, pp. 1104–1116, 2015.
- [43] Yeni, Yeni, S. Supandi, and Y. Khalishah, “HKSA dan Penambatan Molekuler Senyawa Turunan Kumarin sebagai Anti Kanker Kolon,” *BIOEDUSCIENCE J. Pendidik. Biol. dan Sains*, vol. 2, no. 1, pp. 47–49, 2018.
- [44] A. Pathak, P. K. Singour, A. K. Srivastava, P. Gouda, S. Kumar, and B. K. Goutam, “Hansch Analysis of Novel Acetamide Derivatives as Highly Potent and Specific MAO-A Inhibitors,” *Cent. Nerv. Syst. Agents Med. Chem.*, vol. 16, no. 2, pp. 143–151, 2016.
- [45] S. E. Adeniji, S. Uba, Uzairu, and Adamu, “QSAR Modeling and Molecular Docking Analysis of Some Active Compounds against *Mycobacterium tuberculosis* Receptor (Mtb CYP121),” *J. Pathog.*, vol. 2018, pp. 1–24, 2018.
- [46] M. Arba, R. Ruslin, N. Nursan, M. Maulidiyah, and D. H. Tjahjono, “Hubungan Kuantitatif Struktur-Aktivitas (HKSA) dan Penambatan Molekul Senyawa Turunan Benzamida sebagai Inhibitor Alosterik Mitogen Enhanced Kinase (MEK),” *J. Kim. Val.*, vol. 4, no. 1, pp. 42–51, 2018.
- [47] R. Hadanu, “A QSAR Analysis of Flavone Derivatives of Antimalarial Compounds Based on PM3 Semi-Empirical Method,” *Asian J. Chem.*, vol. 30, no. 1, pp. 148–156, 2018.
- [48] A. P. Widiyana, “Desain Komputasi dari Turunan Senyawa Kuinazolin-4(3H)-on sebagai Inhibitor Siklooksigenase-2 (COX-2),” *J. Farm. Sains dan Prakt.*, vol. 7, no. 2, pp. 163–170, 2021.
- [49] L. Agustina and K. Kasmui, “Studi Komputasi Aktivitas Senyawa Turunan Santon Sebagai Antikanker Leukemia Myeloid Kronik K562,” *Indones. J. Math. Nat. Sci.*, vol. 44, no. 1, pp. 1–11, 2021.
- [50] S. B. Utomo, Fajar Sanubari, B. Utami, and N. D. Nurhayati, “Analisis

Hubungan Kuantitatif Struktur dan Aktivitas Analgesik Senyawa Turunan Meperidin Menggunakan Metode Semiempiris AM1,” *JKPK (Jurnal Kim. Dan Pendidik. Kim.)*, vol. 2, no. 3, pp. 158–168, 2017.

- [51] H. Widiyanti, C. Banon, Adfa, and Morina, “Analisis Hubungan Kuantitatif Struktur terhadap Aktivitas Turunan Senyawa Cubebin sebagai Antikanker dengan Metode Recife Model 1 (RM1),” *BENCOOLEN J. Pharm.*, vol. 1, no. 1, pp. 46–58, 2021.
- [52] M. N. Gomes *et al.*, “QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity,” *Eur. J. Med. Chem.*, vol. 137, pp. 126–138, 2017.
- [53] J. La Kilo and A. La Kilo, “Kajian HKSA Antimalaria Senyawa Turunan Quinolon-4(1H)-imines Menggunakan Metode MLR-ANN,” *Jambura J. Chem.*, vol. 1, no. 1, pp. 21–26, 2019.
- [54] A. La Kilo, L. O. Aman, I. Sabihi, and J. La Kilo, “Studi Potensi Pirazolin Tersubstitusi 1-N Dari Tiosemikarbazon Sebagai Agen Antiamuba Melalui Uji *in silico*,” *Indo. J. Chem. Res.*, vol. 7, no. 1, pp. 9–24, 2019.
- [55] D. S. F. Ramadhan, R. Rusli, T. Fakhri, and Muhammad, “Hubungan Kuantitatif Struktur-Aktivitas dan Desain Senyawa Novel Phenyl Benzimidazoles sebagai Penghambat Wnt/ β -Catenin untuk Terapi Pancreatic Ductal Adenocarcinoma,” *J. Sains dan Kesehat.*, vol. 5, no. 5, pp. 584–590, 2023.
- [56] Y. Yeni and R. A. Rachmania, “The Prediction of Pharmacokinetic Properties of Compounds in *Hemigraphis alternata* (Burm.F.) T. Ander Leaves Using pkCSM,” *Indones. J. Chem.*, vol. 22, no. 4, pp. 1081–1089, 2022.
- [57] T. C. Beck, K. R. Beck, J. Morningstar, M. M. Benjamin, and R. A. Norris, “Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs,” *Pharmaceuticals*, vol. 14, no. 5, p. 472, 2021.
- [58] D. E. V. Pires, T. L. Blundell, Ascher, and D. B., “pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures,” *J. Med. Chem.*, vol. 58, no. 9, pp. 4066–4072, 2015.

- [59] N. Kanikkannan, “Technologies to Improve the Solubility, Dissolution and Bioavailability of Poorly Soluble Drugs,” *J. Anal. Pharm. Res.*, vol. 7, no. 1, pp. 1–8, 2018.
- [60] S. S. Abdullah *et al.*, “Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada Pericarpium Pala (*Myristica fragrans*) secara Artificial Intelligence,” *Chem. Prog.*, vol. 14, no. 2, pp. 86–90, 2021.
- [61] Pires, T. L. Blundell, Ascher, and D. B, *pkCSM : predicting small-molecule pharmacokinetic properties using graph-based signatures*. 2015.
- [62] K. V. Ruddraraju *et al.*, “Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for *Mycobacterium tuberculosis* Protein Tyrosine Phosphatase B,” *J. Med. Chem.*, vol. 63, no. 17, pp. 9212–9227, 2020.
- [63] N. D. Thanh *et al.*, “1H-1,2,3-Triazole–4H-chromene–D-glucose hybrid compounds: Synthesis and inhibitory activity against *Mycobacterium tuberculosis* protein tyrosine phosphatase B,” *Arch. Pharm. (Weinheim)*., vol. 356, no. 3, pp. 1–21, 2022.
- [64] S. R. Patel, R. Gangwal, A. T. Sangamwar, and R. Jain, “Synthesis, biological evaluation and 3D QSAR study of 2,4-disubstituted quinolines as anti-tuberculosis agents,” *Eur. J. Med. Chem.*, vol. 93, pp. 511–522, 2015.
- [65] P. Purwaniati, F. Imanulloh, and A. Asnawi, “Studi HKSA Senyawa Turunan 4-(3-nitrophenyl)-thiazol-2-ylhidrazone sebagai Inhibitor Monoamin Oksidase B,” *Pharm. J. Farm. Indones. (Pharmaceutical J. Indones.)*, vol. 19, no. 1, p. 21, 2022.
- [66] I. Imelda, “Optimalisasi Struktur II-Konjugasi Pada Zat Warna Organik Tipe D-Π-a,” *J. Res. Educ. Chem.*, vol. 2, no. 2, pp. 61–63, 2020.
- [67] H. Widiyanti, C. Banon, and M. Adfa, “Analisis Hubungan Kuantitatif Senyawa Cubebin Sebagai Antikanker Dengan Metode Recife Model 1 (RM1),” *Bencoolen J. Pharm.*, vol. 1, no. 1, pp. 46–58, 2021.
- [68] P. Iswanto, I. M. Firdaus, A. F. Dafaalhaq, A. G. Ramadhani, M. P. Saputri, and H. Ekowati, “Quantitative Structure-Activity Relationship of 3-Thiocyanate-1H-Indoles Derived Compounds as Antileukemia by AM1, PM3, and RM1 Methods,” *J. Kim. Sains dan Apl.*, vol. 26, no. 3, pp. 111–

114, 2023.

- [69] A. M. Silva, C. Martins-Gomes, S. S. Ferreira, E. B. Souto, and T. Andreani, "Molecular Physicochemical Properties of Selected Pesticides as Predictive Factors for Oxidative Stress and Apoptosis-Dependent Cell Death in Caco-2 and HepG2 Cells," *Int. J. Mol. Sci.*, vol. 23, no. 15, pp. 13–21, 2022.
- [70] D. M. Khaled, M. E. Elshakre, M. A. Noamaan, H. Butt, M. M. A. Fattah, and D. A. Gaber, "A Computational QSAR, Molecular Docking and *in vitro* Cytotoxicity Study of Novel Thiouracil-Based Drugs with Anticancer Activity against Human-DNA Topoisomerase II," *Int. J. Mol. Sci.*, vol. 23, no. 1, pp. 1–24, 2022.
- [71] Y. Yeni, S. Supandi, and Y. Khalishah, "HKSA dan Penambatan Molekuler Senyawa Turunan Kumarin sebagai Anti Kanker Kolon," *Bioeduscience*, vol. 2, no. 1, p. 45, 2018.
- [72] D. Kesuma *et al.*, "Hansch analysis by QSAR model of curcumin and eight of its transformed derivatives with antimicrobial activity against *Staphylococcus aureus*," *J. Pharm. Pharmacogn. Res.*, vol. 12, no. 5, pp. 1008–1020, 2024.
- [73] A. Asnawi, S. Riyadi, A. N. Usman, E. Febrina, and R. Rendrika, "HKSA dan Penambatan Molekul Dari Turunan Senyawa Pyrido [3,4-b] Indol yang Berpotensi sebagai Antikanker Pankreas," *J. Farm. Malahayati*, vol. 3, no. 2, pp. 111–125, 2020.
- [74] J. Bina *et al.*, "Analisis Hubungan Kuantitatif Struktur Aktivitas (HKSA) Anti- Kanker Senyawa Turunan Benzoxazole," *J. Kesehatan. dan Sci.*, vol. 21, no. 2, pp. 87–95, 2025.
- [75] M. Arba, R. Andriansyah, and M. Leonita, "Studi Hubungan Kuantitatif Struktur Aktivitas Senyawa Turunan Meisoindigo sebagai Inhibitor CDK4," *J. Kim. Ris.*, vol. 1, no. 2, pp. 129–134, 2016.
- [76] S. Paramita, M. P. S, E. V. Y.D., Nasrokhah, and P. Iswanto, "Pemilihan Metode Perhitungan Kimia Komputasi Semi-empiris untuk Pengembangan 1,3,4-Thiadiazole," *Indones. J. Chem. Res.*, vol. 8, no. 1, pp. 51–56, 2020.
- [77] S. Z. Aulia, "Hubungan Kuantitatif Struktur–Aktivitas Dan Penambatan

Molekul Senyawa Analog O–Metil Kuersetin Sebagai Inhibitor Epidermal Growth Factor Receptor–Tyrosine Kinase (Egfr–Tk),” 2023.

- [78] A. La Kilo, L. O. Aman, I. Sabihi, and J. La Kilo, “Studi Potensi Pirazolin Tersubstitusi 1-N dari Tiosemikarbazon Sebagai Agen Antiamuba Melalui Uji *in silico*,” *Indo. J. Chem. Res.*, vol. 7, no. 1, pp. 9–24, 2019.
- [79] N. A. Meanwell, “Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design,” *J. Med. Chem.*, vol. 61, no. 14, pp. 5822–5880, 2018.
- [80] M. Atta *et al.*, “Novel Fluorinated Biphenyl Compounds Synthesized via Pd (0) - Catalyzed Reactions : Experimental and Computational Studies,” *ACS Omega*, vol. 8, no. 2, pp. 29414–29423, 2023.
- [81] M. Guinan, C. Benckendor, M. Smith, and G. J. Miller, “Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues,” *Molecules*, vol. 25, no. 1, pp. 1–25, 2020.
- [82] B. M. A. Sanches and E. I. Ferreira, “Is Prodrug Design an Approach to Increase Water Solubility,” *Int. J. Pharm.*, vol. 4, no. 1, pp. 1–11, 2019.
- [83] C. A. Bonito *et al.*, “Probing the Allosteric Modulation of P-Glycoprotein: A Medicinal Chemistry Approach Toward the Identification of Noncompetitive P-Gp Inhibitors,” *ACS Omega*, vol. 8, no. 12, pp. 11281–11287, 2023.
- [84] A. M. E. Jansen, H. Paul, and R. J. M. Brüggemann, “High Variability in Isavuconazole Unbound Fraction in Clinical Practice : A Call to Reconsider Pharmacokinetic / Pharmacodynamic Targets and Breakpoints,” *Clin. Pharmacokinet.*, vol. 62, no. 12, pp. 1695–1699, 2023.
- [85] O. Nursanti, “Validasi Penambatan Molekul Untuk Mendapatkan Ligan Akif Pada Reseptor Cyclooxygenase 2,” 2021.
- [86] A. Gayatri, P. Ascobat, and R. Setiabudy, “Implikasi Klinis Variasi Jumlah Copy Gen CYP2D6,” *Generics J. Res. Pharm.*, vol. 3, no. 2, pp. 74–82, 2023.
- [87] M. Vander Schaaf *et al.*, “CYP3A4 drug metabolism considerations in pediatric pharmacotherapy,” *Med. Chem. Res.*, vol. 33, no. 12, pp. 2221–

2235, 2024.

- [88] Q. Shubbar, A. Alchakee, K. W. Issa, A. J. Adi, A. I. Shorbagi, and M. Saber-Ayad, "From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice," *Front. Pharmacol.*, vol. 15, no. 1, pp. 1–12, 2024.
- [89] C. Huang *et al.*, "Sirtuins: Research advances on the therapeutic role in acute kidney injury," *Phytomedicine*, vol. 101, p. 154122, 2022.
- [90] Y. Wei *et al.*, "Investigation of *in silico* studies for cytochrome P450 isoforms specificity," *Comput. Struct. Biotechnol. J.*, vol. 23, no. August, pp. 3090–3103, 2024.
- [91] M. Redka, S. Baumgart, D. Kupczyk, and T. Kosmalski, "Lipophilic Studies and *in silico* ADME Profiling of Biologically Active 2-Aminothiazol-4 (5 H) -one Derivatives," *Int. J. Mol.*, vol. 24, no. 1, pp. 1–15, 2023.
- [92] D. A. N. Aktivitas and I. Brazilein, "Studi *in silico* Sifat Farmakokinetik, Toksisitas, dan Aktivitas Imunomodulator Brzilein Kayu Secang Terhadap Enzim 3-Chymotrypsin-Like Cysteine Protease Corona Virus," *J. Indones. Lab. Sci.*, vol. 1, no. 1, pp. 76–90, 2020.
- [93] S. W. Sari, A. Wilapangga, A. N. Sari, and S. Astriani, "Studi *in silico* Potensi Farmakokinetik Dua Senyawa Dari Tanaman Kenaf (*Hibiscus cannabinus* L .) Untuk Prediksi Toksisitas," *J. Kesehat. dan Sci.*, vol. 19, no. 2, pp. 70–79, 2023.
- [94] A. Peter *et al.*, "Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2 , 3-dioxygenase in human breast cancer cells," *Toxicol. Appl. Pharmacol.*, vol. 1, no. 1, pp. 1–12, 2020.
- [95] A. E. Caprifico, P. J. S. Foot, E. Polycarpou, and G. Calabrese, "Overcoming the protein corona in chitosan-based nanoparticles," *Drug Discov. Today*, vol. 26, no. 8, pp. 1–16, 2021.
- [96] I. Izatunnafis, Y. B. Murti, and B. S. Ari Sudarmanto, "*In silico* Pharmacokinetic and Toxicity Prediction of Compounds from *Andrographis paniculata* (Burm.f.) Nees.," *J. Food Pharm. Sci.*, vol. 11, no. 2, pp. 830–838, 2023.

- [97] I. Karimi, L. J. Mohammad, A. Suvitha, Z. Haidari, and H. B. Schiöth, “Comprehensive overview of the toxicities of small-molecule cryoprotectants for carnivorous spermatozoa: foundation for computational cryobiotechnology,” *Front. Toxicol.*, vol. 7, no. 1, pp. 1–18, 2025.
- [98] O. Nursanti, A. Aziz, and G. Hadisoebroto, “Prediksi Toksisitas dan Farmakokinetika untuk mendapatkan Kandidat Obat Analgesik,” *J. Noncommunicable Dis.*, vol. 3, no. 1, pp. 34–46, 2023.